Human carboxylesterase 1 (CES1) is a serine esterase that hydrolyzes various exogenous compounds. Single nucleotide polymorphisms (SNPs) of CES1 may lead to inter-individual metabolic variability of its substrates. The allele and haplotype frequencies of known SNPs have been demonstrated to vary among ethnic groups. We analyzed genetic variations of CES1 in a Korean population. Direct sequencing of all exons and flanking regions of the CES1 gene was performed on samples obtained from 200 Koreans. We identified 41 SNPs. The most frequent SNPs was -914G>C (frequency: 99.5%), followed by 4256G>A (frequency: 65.8%), -75T>G (frequency: 59.3%). Haplotype analysis using the identified SNPs revealed fifteen haplotypes (≥1% haplotype frequency) in our samples. The most frequent haplotype was Hap1 (frequency: 15.4%). Among the identified 41 SNPs, nine of which are novel variants and 14 SNPs were nonsynonymous variants. Using the functional predictive software PolyPhen-2, the G19V, E221G, and A270S variants were predicted to be most likely damaging to the function and structure of CES1. In-vitro analyses for two of these variants have been previously performed; however, functional evaluation of E221G (11657A>G, rs200707504) still needs to be conducted. Therefore, further studies are warranted to characterize the functional impact of E221G on CES1 activity.
Introduction
Human carboxylesterases (CES) are serine esterases that play an important role in phase I drug metabolism. CES enzymes hydrolyze diverse xenobiotic and endogenous substrates that contain carboxylic acid esters, carbamates, thioesters, and amide compounds. [1] [2] [3] [4] Two major subfamilies of identified CES are human carboxylesterase 1 (CES1) and human carboxylesterase 2 (CES2). [2, 4] CES1 gene is located on chromosome 16q13-q22.1 and contains 14 exons. [3, 5] To date (29-Apr-2014), a total of 1107 single nucleotide polymorphisms (SNPs) in CES1 have been documented in the NCBI SNP database (http://www.ncbi. nlm.nih.gov).
CES1 preferentially hydrolyzes a variety of substrates possessing a large acyl group and a small alcohol group, such as methylphenidate, cocaine, heroin, meperidine, demerol, lidocaine, clopidogrel, lovastatin, delapril, temocapril, imidapril, and oseltamivir. [2, 6, 7] In-vitro functional studies have demonstrated that the G143E and the D260fs variants have reduced catalytic function, resulting in the disruption of hydrolytic activity of CES1. [8, 9] In a single-dose pharmacokinetic study, these two CES1 mutations were identified in one subject who displayed 7-fold higher total methylphenidate (i.e., combined d-and l-isomers) concentrations compared to that of other subjects (n=19). [2, 9] In addition, -75T>G polymorphism was associated with the reduced appetite in attention deficit-hyperactivity disorder (ADHD) youths treated with methylphenidate [10] and the isoniazid-induced hepatotoxicity in latent tuberculosis infection patients. [11] Taken together, these findings suggest that CES1 gene variants can lead to clinically significant alterations in
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Translational and Clinical Pharmacology pharmacokinetic profiles and drug response of CES1 substrates. [2, 8] Although their functional consequences remain uncertain, several CES1 variants have been reported in NCBI SNP database. The CES1 allele and estimated haplotype frequencies showed significant differences between African and European populations. [5] However, the exploration of CES1 polymorphisms and their allele and haplotype frequencies in a Korean population have not been performed. We obtained 200 samples from healthy Korean subjects and sequenced the CES1 gene to characterize the polymorphisms that are present in a Korean population. Ideally, this may lead to optimized personalized pharmacotherapy in Koreans, particularly for frequently used prescription drugs that are CES1 substrates.
Methods
Whole blood samples from a total of 200 healthy male Korean subjects were used in this study. Samples were stored in the DNA Repository of the Seoul National University Hospital (SNUH). All of the subjects provided written informed consent before participating in the study. This study was approved by the Institutional Review Board of SNUH. Personal information was blinded, and the samples were delivered to the Pharmacogenomics Research Center of Inje University, where DNA extraction, purification and sequencing were performed. Genomic DNA was isolated from whole blood cells from the study sub- 
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Translational and Clinical Pharmacology jects using the Qiagen DNA Blood Mini Kit (Qiagen, Hilden, Germany). To differentiate from a CES1 pseudogene, we first performed long polymerase chain reaction (PCR) using primers to specifically amplify CES1 (Table 1) . To specifically amplify CES1, we conducted long PCR in separate regions, PromoterExon6 and Exon7-Exon14, before performing nested PCR in each exon. The initial long PCR was performed in a total reaction volume of 50 μL in the presence of 250 ng of genomic DNA, Z-taq buffer, 3.0 mM MgCl 2 , 0.2 M primers, and 1 μM dNTP using Z-taq (Takara Shuzo, Tokyo, Japan). The PCR conditions for this initial amplification were 30 cycles at 94°C for 1 min, 98°C for 5 sec, and 68°C for 3 min 20 sec. Nested PCR was conducted in total volume of 30 μL with 20 ng of the initial PCR product, D-taq buffer, 0.5 M primers, and 250 mM dNTP using D-taq (Sun Genetics, Daejeon, Korea). The nested PCR conditions were as follows: initial denaturation at 94°C for 1 min, followed by 35 cycles of 98°C for 20 sec, 64-65°C for 30 sec, 72°C for 30 sec-1 min, and a final elongation step at 72°C for 5 min. All primer sequences and the annealing temperatures are listed in detail in Table 1 . After DNA purification, PCR products were directly sequenced using ABI PRISM 3130 DNA Analyzer (Applied Biosystems, Foster City, CA). Haplotype frequencies were estimated using Haploview ver. 4.2 software (http://www.broad. mit.edu/mpg/haploview/). In-silico analyses were conducted to predict the possible impact of amino acid substitutions on the structure and function of the CES1 protein using PolyPhen-2 software version 2.2.2 (http://genetics.bwh.harvard.edu/pph2). [12, 13] Because a CES1 protein identifier was unavailable, we used the p23141 protein identifier as the reference, which is considered to be the most similar to the CES1 protein identifier. However, when compared to the CES1 reference protein identifier, the p23141 had an amino acid deletion of alanine at position 18. Therefore, when conducting amino acid substitution analysis using PolyPhen-2 software, we removed position 18 from the results position value. The analysis results are represented as 4 categories: probably damaging, possibly damaging, benign, and unknown.
Results
The distribution of alleles is presented in Table 2 . The -914G>C, -4256G>A, and -75G>C variants were frequently reported with allele frequency of 99.5%, 65.8%, and 59.3%, respectively. A total of 15 common haplotypes (≥1% haplotype frequency) were identified. The most frequent haplotype was Hap1 (frequency: 15.4%), followed by Hap2 (frequency: 12.5%) and Hap 3 (frequency: 12.3%) ( Table 3) . A total of 41 SNPs were identified in this study. Nine novel SNPs were identified in the study population, -722G>A, -610G>A, -332T>G, -161A>G, 15C>T, 16094A>G, 22280C>T, 22445A>T, and 26503C>A. Among the total SNPs identified, 14 SNPs were located in coding regions, and all of these SNPs were nonsynonymous variants (Table 2) . Haplotype  26503C>A  22445A>T  22359C>A  22351C>T  22280C>T  22041T>G  19923T>C  19917G>A  16094A>G  13447A>G  13423G>T  12630C>T  11720C>G  11657A>G  11607C>A  6635A>G  4363C>T  4256G>A  4085G>T  4067A>C  73insT  68A>G  34T>G  19A>G  16T>C  15C>T  11G>C  -2C>G  -20A>G  -21G>C  -30G>A  -39A>G  -46A>G  -75T>G  -161A>G  -322T>G  -610G>A  -722G>A  -757delC  -914G>C -1114G>A Frequency (%)
Hap 14 C A A C C G C A A A G C C G C A T G G A -A T A T C G C A G G A A G A T G G -C G 1.9 Hap 15 C A A T C G C A A A G C C A C A T G G A T A T A T C G C A G G A A T A T G G C C A 1.6
The data ≥ 1% in haplotype frequency presented.
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Discussion
Because CES1 is considered to be the most important hydrolytic enzyme, variations in the CES1 gene can influence substrate pharmacokinetic and/or pharmacodynamic properties and may lead to increases in adverse effects, toxicity, sensitivity, or resistance. [14, 15] Studies examining the potential therapeutic implications of CES1 gene variants have been extensively investigated and reported in biomedical literature. [2, 15] In this study, we evaluated the frequencies of the CES1 genetic variations and their allele and haplotype frequencies in Koreans. The SNP -914G>C showed the highest rate of CES1 gene polymorphism. The next frequently reported SNPs were 4256G>A and -75T>G. Regarding CES1 haplotype frequency, Hap1 exhibited the highest frequency in our samples.
CES1 gene allele and haplotype frequencies have distinct ethnic differences. [2, 5, 8, 14, 16] The minor allele frequency (MAF) of G143E was estimated to be 3.7%, 4.3%, 2.0%, and 0% in European-American, African-American, Hispanic, and Asian populations, respectively. [2, 8, 16] In addition, the allele frequency of the -816A>C polymorphism was 30.9%, 23.8%, and 24.8% in Chinese Yao population, Chinese Han population, and Japanese, respectively. [14, 17] As expected, the G143E polymorphism, which has been reported to be 0% in Asian populations [2, 8, 16 ] and the D260fs polymorphism, which has been observed to be a rare variant in all ethnic groups [15] were not found in this study. On the other hand, the -816A>C variants, which has been reported more than 20% in Asian, were not observed in this study. To our best knowledge, this is the first study to explore CES1 polymorphisms and their allele and haplotype frequencies in a Korean population. Among the 14 nonsynonymous SNPs identified, three three variants were expected to alter human protein structure and function. G19V, E221G, and A270S were classified as most likely damaging (score: 0.992), possibly damaging (score: 0.937), and possibly damaging (score: 0.761), respectively. In our insilico prediction analysis using PolyPhen-2 software, G19V and A270S were denoted as G18V and A269S, respectively, after inserting p23141 protein sequence. In previously performed invitro functional studies, the CES1 variants G18V and A269S did not produce significant effects on CES1 mediated metabolism of substrates including clopidogrel and methylphenidate. [15] However, the effect of E221G (11657A>G, rs200707504; 2% frequency in Koreans) on CES1 enzymatic activity has not been characterized to date. Therefore, additional studies, including in-vitro functional analysis and clinical studies in humans, are needed to elucidate the role of the E221G variant in phase I drug biotransformation. These studies regarding CES1 genetic variants will have the potential to provide clinically relevant information about the optimal use of CES1 drug substrates by predicting pharmacokinetic profiles and drug responses.
